Impact of drug policy on regional trends in ezetimibe use

Circulation: Cardiovascular Quality and Outcomes

Volumn 7, Issue 4, 2014, Pages 589-596

  Lu, Lingyun ^a,b   Krumholz, Harlan M ^a,c,d   Tu, Jack V ^e,f,g   Ross, Joseph S ^c,d   Ko, Dennis T ^e,f,g   Jackevicius, Cynthia A ^a,b,e,f,h  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Robert Wood Johnson Clinical Scholars Program   (United States)

^e INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^h UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Drug utilization; Ezetimibe; Health policy

Indexed keywords

EZETIMIBE; SIMVASTATIN; AZETIDINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PRESCRIPTION DRUG;

ARTICLE; ATHEROSCLEROSIS; CANADA; COHORT ANALYSIS; DRUG USE; HEALTH SERVICE; HUMAN; HYPERCHOLESTEROLEMIA; POLICY; PRIORITY JOURNAL; TREND STUDY; CLINICAL TRIAL; DRUG COST; DYSLIPIDEMIAS; FOLLOW UP; HEALTH CARE POLICY; MULTICENTER STUDY; RETROSPECTIVE STUDY;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CANADA; DRUG COSTS; DYSLIPIDEMIAS; EZETIMIBE; FOLLOW-UP STUDIES; HEALTH POLICY; HUMANS; PRESCRIPTION DRUGS; RETROSPECTIVE STUDIES;

EID: 84925842112     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.114.001023     Document Type: Article

References (43)

1. Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy: The role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation. 2003;107: 3124-3128.
2. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2C008;358: 1431-1443.
3. Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, Griffen L, Taylor AJ. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis). J Am Coll Cardiol. 2010;55: 2721-2726.
4. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359: 1343-1356.
5. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet. 2011;377: 2181-2192.
6. Lu L, Krumholz HM, Tu JV, Ross JS, Ko DT, Jackevicius CA. Impact of the ENHANCE Trial on the use of ezetimibe in the United States and Canada. Am Heart J. 2014;167: 683-689.
7. McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement-recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol. 2006;22: 913-927.
8. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol. 2009;25: 567-579.
9. Lau DT, Briesacher BA, Touchette DR, Stubbings J, Ng JH. Medicare Part D and quality of prescription medication use in older adults. Drugs Aging. 2011;28: 797-807.
10. Demers V, Melo M, Jackevicius C, Cox J, Kalavrouziotis D, Rinfret S, Humphries KH, Johansen H, Tu JV, Pilote L. Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures. CMAJ. 2008;178: 405-409.
11. Marra CA, Lynd LD, Anis AH, Esdaile JM. Approval process and access to prescription drugs in Canada. Arthritis Rheum. 2006;55: 9-11.
12. A report of the Ontario citizens' council private drug insurance in Ontario. Ontario Citizens' Council. March 15, 2012.
13. Drug expenditure in Canada: 1985-2012. Ottawa, Canada: Canadian Institute for Health Information; 2013.
14. British Columbia PharmaCare program formulary. http://www.health.gov. bc.ca/pharmacare/benefitslookup/faces/Search.jsp. Accessed January 2, 2014.
15. Alberta Health: Drug benefit list-ezetimibe. https://idbl.ab.bluecross.ca/idbl/lookupDinPinDetail.do?productID=0000027417. Accessed January 2, 2014.
16. Regie de l'assurance maladie Quebec. Registry-list of medications. http://www.ramq.gouv.qc.ca/en/regie/legal-publications/pages/list-medications. aspx. Accessed January 2, 2014.
17. Ontario Drug Benefit program formulary. https://www.healthinfo.moh.gov.on.ca/formulary/SearchServlet?searchType=luNoteQuery&phrase=e xact&keywords=240600049. Accessed January 2, 2014.
18. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 2002;346: 822-829.
19. Smalley WE, Griffin MR, Fought RL, Sullivan L, Ray WA. Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients. N Engl J Med. 1995;332: 1612-1617.
20. Hamel MB, Epstein AM. Prior-authorization programs for controlling drug spending. N Engl J Med. 2004;351: 2156-2158.
21. Jackevicius CA, Tu JV, Demers V, Melo M, Cox J, Rinfret S, Kalavrouziotis D, Johansen H, Behlouli H, Newman A, Pilote L. Cardiovascular outcomes after a change in prescription policy for clopidogrel. N Engl J Med. 2008;359: 1802-1810.
22. Health Canada. Notice of compliance. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/index-e.html. Accessed February 2, 2014.
23. Health Canada. Drugs and Health Products. http://webprod5.hc-sc.gc.ca/dpd-bdpp/dispatch-repartition.do?lang=eng. Accessed March 15, 2014.
24. Statistics Canada. Population and dwelling counts, for Canada, provinces and territories, 2011 and 2006 censuses. http://www12.statcan.ca/census-recensement/2011/dp-pd/hlt-fst/pd-pl/Table-Tableau.cfm?LANG=Eng&T=101&S=50&O=A. Accessed March 20, 2014.
25. Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM. Use of fibrates in the United States and Canada. JAMA. 2011;305: 1217-1224.
26. IMS Health Inc. Information sources: Pharmacies. http://www.imshealth.com/portal/site/imshealth/menuitem.3e17c48750a3d98f53c753c71ad8c2 2a/?vgnextoid=abb6e590cb4dc310VgnVCM100000a48d2ca2RCRD#Ph armacies. Accessed January 5, 2014.
27. Tu K, Mamdani MM, Jacka RM, Forde NJ, Rothwell DM, Tu JV. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ. 2003;168: 553-557.
28. Majumdar SR, McAlister FA, Soumerai SB. Synergy between publication and promotion: Comparing adoption of new evidence in Canada and the United States. Am J Med. 2003;115: 467-472.
29. Statistics Canada. 2006 Census of Canada. http://www12.statcan.ca/english/census06/home/Index.cfm. Accessed February 2, 2014.
30. Hipel KW, Mcleod AI, Lennox WC. Advances in Box-Jenkins modeling. 1. Model construction. Water Resour Res. 1977;13;567-575.
31. Dickey DA, Fuller WA. Distribution of the estimators for autoregressive time series with a unit root. J Am Stat Assoc. 1979;74: 427-431.
32. Mcleod AI, Hipel KW, Lennox WC. Advances in Box-Jenkins modeling 2. Applications. Water Resour Res. 1977;13;577-586.
33. The Heart and Stroke Foundation in Canada: Statistics. http://www. heartandstroke.com/site/c.ikIQLcMWJtE/b.3483991/k.34A8/Statistics. htm#heartdisease. Accessed March 20, 2014.
34. Morgan S, Bassett K, Mintzes B. Outcomes-based drug coverage in British Columbia. Health Aff (Millwood). 2004;23: 269-276.
35. Christian-Herman J, Emons M, George D. Effects of generic-only drug coverage in a Medicare HMO. Health Aff (Millwood). 2004;W4: 455-468.
36. Mamdani M, Warren L, Kopp A, Paterson JM, Laupacis A, Bassett K, Anderson GM. Changes in rates of upper gastrointestinal hemorrhage after the introduction of cyclooxygenase-2 inhibitors in British Columbia and Ontario. CMAJ. 2006;175: 1535-1538.
37. Marshall DA, Willison DJ, Grootendorst P, LeLorier J, Maclure M, Kulin NA, Sheehy OE, Warren L, Sykora K, Rahme E. The effects of coxib formulary restrictions on analgesic use and cost: Regional evidence from Canada. Health Policy. 2007;84: 1-13.
38. Tunis SR, Stryer DB, Clancy CM. Clancy. Practical clinical trials: Increasing the value of clinical research for decision making in clinical and health policy. J Am Med Assoc. 2003;290: 1624-1632.
39. McMahon M, Morgan S, Mitton C. The Common Drug Review: A NICE start for Canada? Health Policy. 2006;77: 339-351.
40. Gotay CC, Katzmarzyk PT, Janssen I, Dawson MY, Aminoltejari K, Bartley NL. Updating the Canadian obesity maps: An epidemic in progress. Can J Public Health. 2013;104: E64-e68.
41. Schneeweiss S, Glynn RJ, Avorn J, Solomon DH. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol. 2005;58: 98-102.
42. Armstrong PW. Do guidelines influence practice? Heart. 2003;89: 349-352.
43. Vandergrift M, Kanavos P. Health policy versus industrial policy in the pharmaceutical sector: The case of Canada. Health Policy. 1997;41: 241-260.